Alnylam Pharmaceuticals (ALNY) Receivables - Other (2020 - 2021)
Alnylam Pharmaceuticals (ALNY) posted Receivables - Other of $500.0 million for Q2 2021, little changed on a QoQ basis from $500.0 million in Q1 2021.
Alnylam Pharmaceuticals (ALNY) Receivables - Other (2020 - 2021) Analysis & Trends
Alnylam Pharmaceuticals' Receivables - Other history runs 2 years deep, the most recent figure standing at $500.0 million for Q2 2021.
- Quarterly Receivables - Other changed N/A year-over-year to $500.0 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $500.0 million (changed N/A YoY) and the FY2020 annual result came in at $500.0 million, changed N/A from the prior year.
- Receivables - Other was $500.0 million for Q2 2021 at Alnylam Pharmaceuticals, roughly flat from $500.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $500.0 million in Q3 2020 and bottomed at $500.0 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 500.00 Mn |
| Jun 30, 2021 | 500.00 Mn |
| Mar 31, 2021 | 500.00 Mn |
| Mar 31, 2021 | 500.00 Mn |
| Dec 31, 2020 | 500.00 Mn |
| Dec 31, 2020 | 500.00 Mn |
| Sep 30, 2020 | 500.00 Mn |
| Sep 30, 2020 | 500.00 Mn |